As shown by several preclinical and clinical studies, CSF1R in combination with anti-PD1 significantly improves the objective remission rates in patients with solid tumors such as glioma, melanoma, urinary bladder cancer, and non-small cell lung cancer [56, 57]. This evidence concerns the gene PDCD1 and melanoma.